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arkinson disease (PD) is the most frequent 
neurodegenerative disorder, affecting about 1% of 
people over 50 years old. It is caused by the progressive 
loss of dopaminergic (DA) neurons, accompanied by the 
accumulation of Lewy bodies, which are abnormal structures 
inside nerve cells that contain proteins such as α-synuclein, 
Parkin, and components of the ubiquitin proteasomal 
pathway (a cellular-degradation pathway). Patients are 
usually treated with levodopa, and although the drug initially 
improves motor symptoms, many patients later develop a 
range of abnormal or uncontrolled muscle movements, called 
dyskinesias. More than 90% of PD cases are sporadic, but 
rare genetic forms may yield invaluable information on the 
pathogenesis of both familial and spontaneous PD.
After mutations affecting Parkin, mutations in PINK1 
(PTEN-induced putative kinase 1) are the second-most 
common cause of autosomal recessive PD (where both 
parents must contribute a defective gene for PD to arise 
in the offspring). Point or truncation mutations in PINK1 
produce PD with a broad phenotypic spectrum, from 
early-onset with atypical features to typical late-onset PD. 
Pathogenic PINK1 mutations—of which about 20 have 
been identiﬁ  ed—annihilate or reduce the kinase activity 
of the protein. A study by Julia W. Pridgeon (Department 
of Pharmacology, Emory University School of Medicine, 
Atlanta, Georgia, United States) and colleages published in 
this issue of PLoS Biology shows that the failure of PINK1 to 
phosphorylate one particular substrate, TRAP1, can sensitize 
cells to the lethal effects of reactive oxygen species.
A Mitochondrial Role in PD
Chemicals that inhibit the mitochondrial electron transport 
complex I or that elicit production of reactive oxygen species 
can induce PD in humans, suggesting that mitochondria, 
which not only produce cellular energy but also control cell 
death, play a major role in human PD [1]. For both neurons 
and non-neuronal cells, mitochondrial membranes are the 
battleground on which opposing signals combat to seal the 
cell’s fate by mitochondrial membrane permeabilization 
(MMP). Factors that regulate MMP, include the pro- and 
anti-apoptotic members of the Bcl-2 family, proteins from 
the mitochondrial permeability transition pore complex 
(PTPC), and a host of interacting partners. Once MMP 
occurs, hydrolases and activators of caspases are released. The 
destructive action of these enzymes, as well as the cessation of 
the vital bioenergetic and redox functions of mitochondria, 
ﬁ  nally cause cell death, meaning that mitochondria 
coordinate the ultimate stage of cellular demise [2].
PINK1 localizes to mitochondria, and experiments in 
the fruit ﬂ  y (Drosophila melanogaster) show that PINK1 and 
DJ1 (another protein that when mutated causes a genetic 
form of PD) act together to prevent neurodegeneration. 
PINK1 loss-of-function mutant phenotypes can be rescued 
by antioxidants; overexpression of Parkin (a ubiquitin E3 
ligase) as well as transgenic expression of the anti-apoptotic 
protein Bcl-2— one of the most potent inhibitors of MMP 
[3–6]—indicate the existence of a pathway that links most of 
the proteins that when defective cause PD. Hence, the study 
of the molecular mechanisms through which PINK1 regulates 
cell death is likely to yield important clues to the pathogenesis 
of familial, and perhaps sporadic, PD. 
Previously it had been shown that overexpression of PINK1 
protects cells from apoptosis induced by the general tyrosine 
kinase inhibitor staurosporine [7,8] and that pathogenic 
mutations of PINK1 that inactivate its serine/threonine 
kinase activity [9] do not protect against cell death, implying 
that its kinase activity is indispensable for this effect. However, 
it has not been known which substrates phosphorylated by 
PINK1 would account for its capacity to inhibit lethal MMP.
PINK Mutations Place Mitochondria at Risk
In this issue of PLoS Biology, Pridgeon and coworkers show 
that the PINK1 mutations that cause PD (such as PINK1 
G309D, L347P, and W437X) have a reduced capacity to 
phosphorylate TRAP1 and to protect mitochondria and 
cells against the fatal consequences of oxidative stress 
(Figure 1). This is a breakthrough in our understanding of 
the mechanisms underlying inherited PD linked to PINK1 
mutations, and it has implications where there is increased 
susceptibility to oxidative stress, such as in the immature 
brain [10]. 
The work by Pridgeon et al. suggests avenues for further 
exploration. Does PINK1 have other molecular targets in 
mitochondria? Pridgeon et al. found at least ten proteins 
that could bind to recombinant PINK1 in vitro—could these 
too be targets for PINK 1? It is intriguing that some PINK1 
mutations cause autosomal recessive PD, yet some cases of 
late-onset PD are associated with heterozygous mutations in 
PINK1 [11]. It is possible that a complete defect in PINK1 
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kinase due to mutation of both PINK1 alleles would cause 
early-onset autosomal recessive PD, yet a partial defect in 
PINK1 kinase would contribute to late-onset autosomal 
dominant PD. 
Future investigations must address the question as to how 
phosphorylated TRAP1 prevents the release of cytochrome 
c from mitochondria. Pridgeon et al. clearly show that it 
was not a question of TRAP1 sequestering of cytochrome 
c. It would be interesting to know whether phosphorylated 
TRAP1 impairs MMP and, if so, through what mechanisms. 
MMP can be triggered in many different ways and TRAP1 is 
a member of the HSP90 family of heat shock proteins, which 
are well known for their multiple cytoprotective effects, such 
as the removal of misfolded proteins or neutralization of pro-
apoptotic proteins [12]. Could this be how TRAP1 prevents 
cell death? 
Interestingly, TRAP1 has nonmitochondrial functions 
that may be regulated by factors other than PINK1. Indeed, 
the abbreviation stands for “tumor necrosis factor receptor–
associated protein 1”. TRAP1 chaperones the retinoblastoma 
protein, thereby affecting cell-cycle regulation [13]. TRAP1 is 
upregulated by the oncogene c-Myc [14] and down-regulated 
in HIV-1–infected cells [15]. This latter process may contribute 
to HIV-1–induced MMP and apoptosis. Moreover, TRAP1 
is suppressed by the HSP90 inhibitor geldanamycin [16], 
suggesting that at least part of the chemosensitizing effects of 
geldanamycin and its analogs might be attributed to an effect 
on TRAP1. Hence, TRAP1 may be involved in the general 
regulation of apoptosis, outside of the central nervous system. 
It remains a mystery why the impaired phosphorylation 
of TRAP1 by mutated PINK1 induces the speciﬁ  c DA 
neurodegeneration seen in PD. PINK1 is not limited to DA 
neurons of the substantia nigra, but is expressed throughout 
the human brain in all cell types, as well as outside the 
brain, and the same applies to TRAP1 [17]. PINK1 was 
detected in a proportion of Lewy bodies both in sporadic 
PD and in PD cases associated with heterozygous mutations 
in the PINK1 gene, which are clinically and pathologically 
indistinguishable from the sporadic cases. Interestingly, 
PINK1 was absent from other protein-ﬁ  lled intracellular 
structures (called inclusions), such as cortical Lewy bodies, 
in neuroﬁ  brillary tangles in Alzheimer disease, in progressive 
supranuclear palsy and corticobasal degeneration, and in 
the glial and neuronal alpha-synuclein positive inclusions in 
multiple system atrophy [17]. These ﬁ  ndings point to speciﬁ  c 
contributions of PINK1 to PD that remain to be explored, 
yet they do not explain why PINK1 mutations compromise 
the survival of DA neurons while leaving other cell types 
unaffected.
A second integral feature of PD pathogenesis is oxidative 
stress. Postmortem investigations have consistently shown that 
oxidative stress is a hallmark of the damaged substantia nigra 
from PD patients. The preferential loss of nigral neurons in 
PD has been attributed to the highly oxidative intracellular 
environment in dopaminergic neurons [18]. Oxidation and 
degradation of the labile transmitter dopamine may induce 
oxidative stress, proteolytic dysfunction, and mitochondrial 
defects, and this may be the underlying reason for the 
selective vulnerability of DA neurons [19]. Oxidative stress 
is intimately linked to other aspects of neurodegeneration, 
such as mitochondrial dysfunction, which may make it 
difﬁ  cult to determine whether oxidative stress leads to, or 
is a consequence of, mitochondrial dysfunction. Inhibition 
of complex I results in enhanced production of ROS, 
and increased ROS levels may in turn inhibit complex I, 
resulting in a vicious cycle of oxidative stress and impaired 
mitochondrial respiration [20]. Furthermore, the toxicity of 
mitochondrial poisons such as 1-methyl-4-phenylpyridium 
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Figure 1. A Mechanism through which PINK1 Mutations under Conditions of Increased Oxidative Stress May Sensitize Dopaminergic Neurons 
to Cytochrome c Release and Subsequent Cell Death, Eventually Causing PDPLoS Biology  |  www.plosbiology.org 1411
ions (MPP+) and rotenone is most pronounced in DA 
neurons, even though they inhibit complex I throughout 
the brain, suggesting that DA neurons are intrinsically 
sensitive to complex I defects [20]. Also, complex I inhibitors 
such as rotenone have been shown to reduce proteasomal 
activity through ATP depletion, leading to increased 
toxicity in neurons with a compromised proteasome, 
thereby constituting a link between mitochondrial activity, 
proteasomal insufﬁ  ciency, impaired clearance of misfolded 
proteins, and cell death [21]. 
As a result, deﬁ  cient PINK1 function might selectively 
affect DA neurons, because DA neurons constitute the cell 
type that is most susceptible to ROS attack in the human 
body. Not withstanding this explanation, impaired PINK1 
function might also render other neurons more susceptible 
to oxidative stress, suggesting that other neurodegenerative 
diseases (e.g., Alzheimer disease) might progress at a faster 
rate when PINK1 is mutated. Similarly, acute brain injuries 
(e.g., stroke or trauma) could be exacerbated in the absence 
of intact PINK1. These issues require urgent clariﬁ  cation 
because they might affect the clinical management of 
neurological diseases well beyond that of PD. 
Next Steps
The future will tell whether the functional exploration of 
PINK1 might furnish new targets for therapy. Theoretically, 
inhibitors of the phosphatase that dephosphorylates TRAP1 
might have a neuroprotective effect on DA neurons Based 
on these speculations, we are cautiously optimistic that small-
molecule inhibitors of kinases may become useful for the 
prevention or treatment of PD.  
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